New Beta Innovation Limited   Report issue

For profit Phase 1 Phase 2
Founded: Burnaby Canada (2007)

Organization Overview

First Clinical Trial
2019
NCT03802292
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

New Beta Innovation Limited

Active Ingredients

Drugs in Phase 2 Trials (1)

yq23 (3 trials)

Drugs in Phase 1 Trials (1)

pembrolizumab (keytruda) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 2